Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144258 | 0.78 | P2RY14 (0.37) | — | |
| SCHEMBL16144610 | 0.78 | ALDH1A1 (0.32) | KIF11LMNASLC6A1SLC6A11 | |
| SCHEMBL16144281 | 0.76 | PDE3A (0.36) | KIF11LMNA | |
| SCHEMBL26355010 | 0.70 | KIF11 (0.36) | KIF11KCNH2LMNAHTTSMN1; SMN2 | |
| SCHEMBL16144259 | 0.69 | P2RY14 (0.36) | — | |
| SCHEMBL25400121 | 0.69 | P2RY14 (0.37) | — | |
| SCHEMBL26355004 | 0.68 | KIF11 (0.40) | KIF11KCNH2LMNAHTTSMN1; SMN2 | |
| SCHEMBL25399622 | 0.67 | TK2 (0.39) | — | |
| SCHEMBL25400989 | 0.67 | HSP90AA1 (0.41) | LMNASMN1; SMN2 | |
| SCHEMBL25400287 | 0.67 | TK2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | KIF11 502/4885KCNH2 4199/4885LMNA 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.